Atossa Genetics -15% on heels of critical FDA report

|About: Atossa Genetics, Inc. (ATOS)|By:, SA News Editor

Atossa Genetics (ATOS -15.3%) slides sharply after the Food and Drug Administration issues a consumer update on nipple aspirators used for breast cancer screening, saying a mammogram is still the best way to detect breast cancer.

The update slammed ATOS' claim that its ForeCYTE Breast Health Test was "literally a Pap smear for breast cancer"; the nipple aspiration test has no such evidence supporting it, the FDA says.

In October, ATOS recalled the breast cancer test from the market.